Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies
Adjuvant PD-1 blockade significantly improves DFS in high-risk cSCC. With the caveats of indirect comparisons and the pending full publication of one of the two trials, these post hoc findings are hypothesis generating and may help inform the selection of high-risk patients deserving adjuvant therapy.
Authors
- Imperia Nuzzolese (ORCID: https://orcid.org/0000-0001-6293-5301)
- Cristiana Bergamini (ORCID: https://orcid.org/0000-0001-7616-5125)
- Lisa Francesca Licitra (ORCID: https://orcid.org/0000-0003-0623-4118)
- Benedetta Lombardi Stocchetti (ORCID: https://orcid.org/0009-0008-7371-3411)
- Arianna Ottini (ORCID: https://orcid.org/0000-0003-4239-8072)
- Salvatore Alfieri (ORCID: https://orcid.org/0000-0001-8485-2275)
- Stefano Cavalieri (ORCID: https://orcid.org/0000-0003-1294-6859)
- Elena Colombo (ORCID: https://orcid.org/0000-0002-5265-5055)
Institutions
- University of Milan (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1016/j.iotech.2025.101557
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00